OaxaCannabis

09/02/2026

Un estudio demostró que el CBD induce la apoptosis en células cancerosas humanas, al tiempo que retrasa los procesos apoptóticos en células de control no malignas. Estos hallazgos subrayan el potencial del CBD como agente terapéutico complementario para el tratamiento del cáncer, destacando sus efectos citotóxicos selectivos sobre las células malignas con un impacto limitado en las células no malignas.
---
Study demonstrated that CBD induces apoptosis in human cancer cells while delaying apoptotic processes in non-malignant control cells. These findings underscore the potential of CBD as an adjunctive therapeutic agent for cancer treatment, highlighting its selective cytotoxic effects on malignant cells with limited impact on non-malignant cells.

https://www.mdpi.com/1422-0067/26/24/12136

Foto de HippoPX.

09/02/2026

Cannabis, particularly low-dose THC and CBD, may improve cognitive function in older adults by reducing brain inflammation, boosting neurogenesis in the hippocampus, and enhancing neural connectivity. It potentially reverses age-related decline by stimulating CB1 receptors, improving memory, learning, and processing speed while preserving brain volume in key areas. 

🗂️Key Mechanisms for Cognitive Improvement 

📑Neuroprotection and Anti-inflammatory Effects: CBD reduces oxidative stress and neuroinflammation, which are common in aging brains and linked to neurodegenerative conditions.

📑Restoring Brain Function via Low-Dose THC: Preclinical studies suggest very low-dose THC can reverse age-related declines in cognitive performance by acting on the endocannabinoid system.

📑Improved Neural Connectivity: Cannabis use in older adults has been associated with greater functional connectivity between the hippocampus and cerebellum, areas vital for memory and learning.

📑Neurogenesis: Daily stimulation of cannabinoid receptors has been shown to increase the growth of new neurons in the hippocampus. 

🗂️Impact on Cognitive Domains:

📑Memory and Processing: Studies have linked lifetime cannabis use to better performance in processing speed, attention, and working memory.

📑Neural Structure: Lifetime use has been associated with larger brain volumes in CB1-rich regions like the caudate, putamen, and hippocampus.

12/11/2025

Los cannabinoides en la investigación preclínica de la sepsis: una revisión exhaustiva.
Los cannabinoides son dianas terapéuticas prometedoras en el tratamiento de la sepsis, ya que mejoran la supervivencia y reducen la inflamación y las lesiones orgánicas. Sin embargo, se notificaron efectos adversos nocivos, cuyos mecanismos moleculares subyacentes aún se desconocen, y es necesario seguir investigando para evaluar sus beneficios y su futuro uso en la investigación clínica.
---
Cannabinoids in preclinical research of sepsis: a scoping review.
Cannabinoids are promising therapeutic targets in the treatment of sepsis, as they improved survival, and reduced inflammation and organ injury. However, deleterious adverse effects were reported, with the underlying molecular mechanisms still unknown, and further research is needed to evaluate their benefits and future use in clinical research.

https://link.springer.com/article/10.1007/s00011-025-02090-9

Foto por formulario PxHere.

07/11/2025

https://neurosciencenews.com/nano-tech-cbd-pain-29910/

A new study shows that CBD delivered through a nano-micelle system can cross the blood–brain barrier and produce rapid neuropathic pain relief.

28/10/2025

https://www.cannabistrades.org/stories/polyploid-and-triploid-cannabis-what-s-the-difference-and-why-does-it-matter

Every living thing, from humans to plants, has chromosomes, tiny packages of DNA that carry genetic information. The number of chromosome sets a plant has is described by the term ploidy.

02/10/2025

Psilocybin Rewire Brain Circuits Tied to Pain and Mood

Researchers have shown that psilocybin, the psychedelic compound in mushrooms, can relieve chronic pain and depression-like symptoms by targeting brain circuits rather than the site of injury.

In mice, a single dose eased suffering for nearly two weeks by modulating serotonin activity in the anterior cingulate cortex.

Unlike opioids, psilocybin worked like a “dimmer switch,” finely tuning signals rather than shutting them off completely.

The findings point to a promising new class of non-addictive treatments for chronic pain and mood disorders.

23/09/2025

https://medicalxpress.com/news/2025-09-body-endocannabinoid-receptor-result-neuropsychiatric.html

Endocannabinoids are similar to the cannabinoids present in cannabis, but they are found naturally in the body. Endocannabinoids—and cannabinoids—work through a signaling system that supports neurodevelopment, but whether manipulating this system prenatally has long-lasting effects remains uncle...

17/09/2025

https://www.goodnewsnetwork.org/depression-patients-treated-with-psychedelic-mushrooms-5-years-ago-are-still-symptom-free/

The study involved participants from a trial published in 2021 that found psilocybin—the primary psychedelic substance produced by mushrooms.

12/09/2025

https://medicalxpress.com/news/2025-09-distinct-psilocybin-oscillations-rat-medial.html

Psychedelics, a class of psychoactive drugs that typically induce peculiar mental states and hallucinations, are still prohibited for recreational use in most countries worldwide. In recent years, some neuroscientists and medical researchers have been exploring the potential therapeutic effects of t...

03/09/2025

Un estudio reveló que la ansiedad, la depresión y el dolor crónico eran las indicaciones más comunes del cannabis medicinal, aunque la situación legal influyó en el consumo y en las afecciones tratadas.
Los participantes declararon diversos métodos de consumo, siendo fumar el más común, aunque también se asoció con el mayor índice de efectos secundarios.
En general, el 32,3% de los participantes calificaron el cannabis de muy eficaz para su afección principal.
---
A study revealed that anxiety, depression, and chronic pain were the most common indications for medical cannabis, although legal status influenced use and conditions treated.
Participants reported a variety of methods of use, with smoking being the most common, although it was also associated with the highest rate of side effects.
Overall, 32.3% of participants rated cannabis as very effective for their primary condition.

https://www.sciencedirect.com/science/article/pii/S2773065425000847

Foto de Kindel Media en Pexels.

27/08/2025

Registro de Cannabis Medicinal del Reino Unido: Un análisis clínico de pacientes con trastorno por consumo de sustancias.
Hubo una mejora asociada en la calidad de vida relacionada con la salud informada por el paciente y una reducción en los opioides prescritos en individuos con trastorno por uso de sustancias tratados con productos medicinales a base de Cannabis. Éstos fueron bien tolerados por la mayoría de los individuos en este análisis de 6 meses.
----
UK Medical Cannabis Registry: A Clinical Analysis of Patients with Substance Use Disorder.
There was an associated improvement in health-related quality of life patient-reported and reduction in prescribed opioids in individuals with substance use disorder treated with Cannabis-based medicinal products. Those were well tolerated by most individuals in this 6-month analysis.

https://karger.com/ear/article/doi/10.1159/000547696/931298/UK-Medical-Cannabis-Registry-A-Clinical-Analysis

Foto de MART PRODUCTION en Pexels.